AstraZeneca partners with insitro on AI-driven drug discovery for MASH, cardiomyopathies

By Public Technologies
  • AstraZeneca entered a drug discovery collaboration and licensing agreement with insitro to develop AI-driven treatments for MASH and cardiomyopathies.
  • Insitro will receive $40 million upfront, with eligibility for up to approximately $1.46 billion in development and commercial milestones.
  • Potential single-digit royalties apply to global commercial sales.
  • The drugmaker will hold exclusive worldwide rights to advance selected programs identified through the collaboration.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Cision (Ref. ID: 202610150600BITN____UKPR__SV_20261015-BIT-3945-0) on October 15, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.